Zohydro v. Massachusetts = Wyeth v. Levine? State Asserts Power To Seek Label Change
This article was originally published in The Pink Sheet Daily
Executive Summary
Arguing for its right to ban Zogenix Inc.’s opioid, Massachusetts contends that FDA clearance of a drug for marketing is a “gateway approval” that does not preempt states from imposing stricter requirements on a product.